The overall objective of our research is to understand the molecular mechanisms that drive immunologic processes and malignancies. It has become clear that the events that control lymphoid differentiation are a result of changing patterns of gene expression. The studies in my laboratory are focused on a class of transcription factors, helix-loop-helix (HLH) proteins, that are in part responsible for the alterations in gene expression during B cell development. One particular class of HLH protein is the E-proteins, that include E12, E47, E2-2, and HEB. E12 and E 47 are encoded by one gene, E2A, and arise through differential splicing. E2-2 and HEB are encoded by different genes. Differentiation of B cells in E2A mutant mice is blocked at a stage prior to immunoglobulin gene rearrangement. These data suggested that E2A is a central regulator in early B cell development. We are now further dissecting the contributions of E2A and other E-proteins in lymphoid differentiation, and we are determining the hierarchy of transcription factors that control lymphoid development.
In addition to their role in lymphoid development, the E2A gene is a key factor in generating pediatric leukemias. Specifically, in pre-B ALL, the E2A HLH domain has been replaced with the homeodomain of PbX1, normally a gene product involved in morphogenesis. We have recently identified a target gene of E2A/Pbx1, encoding a novel member of the FGF growth factor family, designated FGF-10. FGF-10 is normally expressed in the retina and midbrain and is inappropriately induced by E2A/Pbx1. We are now examining the mechanism of how E2A/Pbx1 and FGF like growth factor contribute to B cell malignancies.
Questions about/problems with this site? Please e-mail the webmaster. © Copyright 2007 Kinship Foundation. All rights reserved.